

<b>Medication:</b> Clopidogrel (Plavix)	<b>PDN:</b> 6984.04	<b>Last Updated:</b> May 5 2024	<b>PMD:</b> Andrew Travers*	<b>PDC:</b> Teena Robinson*	Page 1 of 2
--	---------------------	------------------------------------	--------------------------------	--------------------------------	-------------

## CLOPIDOGREL (Plavix)

### 1.0 Classification

- Platelet aggregation inhibitor/antiplatelet (clopidogrel is not an anticoagulant).

### 2.0 Mechanism of Action

- Irreversible blockade of adenosine diphosphate (ADP) receptor on platelet cell membranes, inhibiting platelet aggregation.

### 3.0 Indications

- For the treatment of ST segment elevation myocardial infarction (STEMI) of less than twelve (12) hours duration and more than twenty (20) minutes duration when TNK is being administered.

### 4.0 Contraindications

- Hypersensitivity
- Active bleeding
- Severe liver impairment or jaundice

### 5.0 Precautions

- None

### 6.0 Route

- May be given PO

### 7.0 Dosage

- **STEMI Receiving Pre-hospital Fibrinolysis:**
  - 300 mg for patients less than 75 years of age
  - 75 mg for patients 75 years of age and older

### 8.0 Supplied

- 75 mg and 300 mg tablets

### 9.0 May Be Given By

- PCP/ICP/ACP/CCP

### 10.0 Adverse Effects

- Chest Pain
- Increased risk of bleeding
- Bruising
- Itching/swelling/rash
- Nosebleed
- Generalized pain
- Influenza-like symptoms

### 11.0 Special Notes

- Standard ischemic chest pain management (ASA, nitroglycerin and opioids for severe pain)

- unresponsive to nitrates) should be continued as well.
- There is an increased risk of bleeding when clopidogrel is administered in conjunction with NSAIDs.
  - Pregnancy category C [if the patient will benefit from a Category C drug, it is generally used]

## **12.0 References**

- Chest Pain Clinical Practice Guideline
- EHS STEMI Reperfusion Worksheet
- Compendium of Pharmaceuticals and Specialties (CPS)

\*Electronically Signed  
Copyright © Emergency Health Services